Protocol
09-039
Full Title
Prospective Randomized, Double Blind, Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess
Purpose
Surgery to remove a pancreatic tumor can sometimes result in complications. For example, after a tumor is removed and the remaining part of the pancreas is attached to the small intestine, there may be some leakage of pancreatic fluid. This fluid can form into an abscess or fistula that needs to be drained. Complications such as these occur in 15 to 20 percent of patients having surgery on the pancreas.
The purpose of this study is to see if an investigational drug called SOM230 (also called Pasireotide) can reduce the risk of these complications. Patients in this study will be randomly assigned to receive SOM230 or a placebo.
Investigator
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must be scheduled for pancreatic surgery (pancreaticoduodenectomy or distal pancreatectomy) at Memorial Sloan-Kettering Cancer Center.
- Patients must be age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Peter Allen at 212-639-5132.
Disease(s)
Hepatobiliary: Pancreatic Cancer
Survivorship
Upper Gastrointestinal: Pancreatic Cancer
Locations
ClinicalTrials.gov
Related Diseases
